Report Sections

See All Reports

Coronavirus Infections (722) Severe Acute Respiratory Syndrome (493) Infection (402) Pneumonia (331) Communicable Diseases (176) Respiratory Distress Syndrome, Adult (161) Acute Lung Injury (126) Respiratory Distress Syndrome, Newborn (126) (114) Syndrome (106) Virus Diseases (85) Pneumonia, Viral (73) Critical Illness (63) Depression (62) Anxiety Disorders (44) Disease (39) Stress Disorders, Post-Traumatic (34) Emergencies (31) Respiratory Tract Infections (31) Inflammation (30) Neoplasms (30) Cardiovascular Diseases (29) Stress Disorders, Traumatic (29) Wounds and Injuries (29) Lung Injury (27) Stress, Psychological (27) Mental Disorders (26) Diabetes Mellitus (25) Hypoxia (25) Depressive Disorder (24) Thrombosis (23) Hypertension (22) Respiratory Tract Diseases (22) Acute Kidney Injury (21) Lung Diseases (21) Disease Progression (18) Olfaction Disorders (18) Embolism (16) Influenza, Human (16) Stroke (16) Arthritis (15) Pulmonary Embolism (15) Respiration Disorders (15) Blood Coagulation Disorders (14) HIV Infections (14) Hemostatic Disorders (14) Thromboembolism (14) Burnout, Psychological (13) Chronic Disease (13) Fibrosis (13) Lung Diseases, Obstructive (13) Multiple Sclerosis (13) Sclerosis (13) Cognitive Dysfunction (12) Diabetes Mellitus, Type 2 (12) Lung Diseases, Interstitial (12) Myocardial Infarction (12) Pulmonary Disease, Chronic Obstructive (12) Pulmonary Fibrosis (12) Respiratory Aspiration (12) Arthritis, Rheumatoid (11) Autism Spectrum Disorder (11) Brain Injuries (11) Chronic Pain (11) Heart Diseases (11) Kidney Diseases (11) Substance-Related Disorders (11) Venous Thrombosis (11) Crohn Disease (10) Diabetes Mellitus, Type 1 (10) Heart Failure (10) Infarction (10) Lung Neoplasms (10) Autistic Disorder (9) Dyspnea (9) Myocarditis (9) Obesity (9) Pneumonia, Ventilator-Associated (9) Pregnancy Complications (9) Brain Injuries, Traumatic (8) Carcinoma (8) Colitis (8) Colitis, Ulcerative (8) Depression, Postpartum (8) Liver Diseases (8) Renal Insufficiency, Chronic (8) Respiratory Syncytial Virus Infections (8) Rheumatic Diseases (8) Ulcer (8) Vitamin D Deficiency (8) Coronary Artery Disease (7) Coronary Disease (7) Dementia (7) Feeding and Eating Disorders (7) Hematologic Neoplasms (7) Infertility (7) Inflammatory Bowel Diseases (7) Kidney Failure, Chronic (7) Parkinson Disease (7) Problem Behavior (7) Pulmonary Valve Insufficiency (7) Venous Thromboembolism (7) Burnout, Professional (6) Collagen Diseases (6) Frailty (6) Immune System Diseases (6) Immunologic Deficiency Syndromes (6) Ischemia (6) Lupus Erythematosus, Systemic (6) Lymphoma (6) Musculoskeletal Pain (6) Overweight (6) Parasomnias (6) Pediatric Obesity (6) Psychotic Disorders (6) RNA Virus Infections (6) Sepsis (6) Shock (6) Spinal Cord Injuries (6) Acute Coronary Syndrome (5) Alcohol Drinking (5) Alcoholism (5) Autoimmune Diseases (5) Breast Neoplasms (5) Carcinoma, Non-Small-Cell Lung (5) Child Development Disorders, Pervasive (5) Convalescence (5) Coronaviridae Infections (5) Cystic Fibrosis (5) Delirium (5) Depressive Disorder, Major (5) Disease Susceptibility (5) Dyssomnias (5) Gastroparesis (5) Hypersensitivity (5) Leukemia (5) Lymphopenia (5) Multiple Organ Failure (5) Myocardial Ischemia (5) Neurologic Manifestations (5) Osteoarthritis (5) Prostatic Neoplasms (5) Renal Insufficiency (5) Alzheimer Disease (4) Asthma (4) Attention Deficit Disorder with Hyperactivity (4) Behavior, Addictive (4) Body Weight (4) Brain Diseases (4) Coinfection (4) Colonic Neoplasms (4) Death (4) Deglutition Disorders (4) Disseminated Intravascular Coagulation (4) Embolism and Thrombosis (4) Fibromyalgia (4) Head and Neck Neoplasms (4) Heart Arrest (4) Hemorrhage (4) Hypertension, Pulmonary (4) Liver Cirrhosis (4) Metabolic Syndrome (4) Migraine Disorders (4) Mycobacterium Infections (4) Neoplasm Metastasis (4) (4) Pancreatic Neoplasms (4) Postoperative Complications (4) Prediabetic State (4) Signs and Symptoms, Respiratory (4) Sjogren's Syndrome (4) Sleep Apnea Syndromes (4) Sleep Initiation and Maintenance Disorders (4) Thrombophilia (4) Vascular Diseases (4) Weight Loss (4) Acquired Immunodeficiency Syndrome (3) Adenoviridae Infections (3) Appendicitis (3) Arrhythmias, Cardiac (3) Arthritis, Psoriatic (3) Asymptomatic Diseases (3) Bronchiectasis (3) Carcinoma, Renal Cell (3) Cardiomyopathies (3) Chilblains (3) Common Cold (3) Cross Infection (3) Dermatitis (3) Developmental Disabilities (3) Digestive System Diseases (3) Dysgeusia (3) Endometriosis (3) Fatigue (3) Fever (3) Gastrointestinal Diseases (3) Giant Cell Arteritis (3) Glucose Intolerance (3) Glucose Metabolism Disorders (3) Hemophilia A (3) Leukemia, Lymphoid (3) Macular Edema (3) Malnutrition (3) Measles (3) Melanoma (3) Metabolic Diseases (3) Mucocutaneous Lymph Node Syndrome (3) (3) Nervous System Diseases (3) Neuroendocrine Tumors (3) Occupational Stress (3) Osteoarthritis, Knee (3) Ovarian Neoplasms (3) Panic Disorder (3) Paramyxoviridae Infections (3) Peripheral Arterial Disease (3) Polymyalgia Rheumatica (3) Precursor Cell Lymphoblastic Leukemia-Lymphoma (3) Pregnancy Complications, Infectious (3) Premature Birth (3) Psychological Trauma (3) Pulmonary Edema (3) Rheumatic Fever (3) ST Elevation Myocardial Infarction (3) Schizophrenia (3) Seizures (3) Sleep Apnea, Obstructive (3) Sleep Wake Disorders (3) Systemic Inflammatory Response Syndrome (3) Taste Disorders (3) Tobacco Use Disorder (3) Triple Negative Breast Neoplasms (3) Ventricular Dysfunction (3) Ventricular Dysfunction, Left (3) Acute Disease (2) Ageusia (2) Agoraphobia (2) Alopecia (2) Alpha 1-Antitrypsin Deficiency (2) Amyotrophic Lateral Sclerosis (2) Anemia, Sickle Cell (2) Angina Pectoris (2) Angioedema (2) Angioedemas, Hereditary (2) Anxiety, Separation (2) Arteritis (2) Asymptomatic Infections (2) Atherosclerosis (2) Atrial Fibrillation (2) Bacterial Infections (2) Behcet Syndrome (2) Bipolar Disorder (2) Caliciviridae Infections (2) Clinical Deterioration (2) Cognition Disorders (2) Colorectal Neoplasms (2) Communicable Diseases, Emerging (2) Compassion Fatigue (2) Compulsive Personality Disorder (2) Congenital Abnormalities (2) Conjunctivitis (2) Dermatitis, Atopic (2) Diarrhea (2) Drug-Related Side Effects and Adverse Reactions (2) Eczema (2) Emphysema (2) Endocrine System Diseases (2) Fatigue Syndrome, Chronic (2) Ganglion Cysts (2) Gastroenteritis (2) Gastroesophageal Reflux (2) Gaucher Disease (2) Glioblastoma (2) Headache (2) Healthcare-Associated Pneumonia (2) Heart Defects, Congenital (2) Heart Failure, Systolic (2) Hematologic Diseases (2) Huntington Disease (2) Hyperglycemia (2) Hyperkinesis (2) Hyperphagia (2) Hypothermia (2) Hypoventilation (2) Idiopathic Pulmonary Fibrosis (2) Intervertebral Disc Degeneration (2) Intestinal Diseases (2) Ischemic Attack, Transient (2) Jaundice (2) Leukemia, Myeloid, Acute (2) Lymphoproliferative Disorders (2) Macular Degeneration (2) Mobility Limitation (2) Mood Disorders (2) Motor Neuron Disease (2) Multiple Myeloma (2) Multiple Sclerosis, Relapsing-Remitting (2) Muscular Dystrophies (2) Mutism (2) Mycoses (2) Myelodysplastic Syndromes (2) Myeloproliferative Disorders (2) Myositis (2) Necrosis (2) Neoplasms, Plasma Cell (2) Nerve Degeneration (2) Neurodevelopmental Disorders (2) Nidovirales Infections (2) Noncommunicable Diseases (2) Nutrition Disorders (2) Obesity, Morbid (2) Obsessive-Compulsive Disorder (2) Oral Manifestations (2) Pain, Postoperative (2) Peripheral Vascular Diseases (2) Phobia, Social (2) Phobic Disorders (2) Pneumonia, Pneumocystis (2) Psoriasis (2) Purpura, Thrombocytopenic, Idiopathic (2) Rare Diseases (2) Recurrence (2) Respiratory Sounds (2) Sarcoidosis (2) Shock, Septic (2) Small Cell Lung Carcinoma (2) Spinal Diseases (2) Sprains and Strains (2) Suicidal Ideation (2) Suicide (2) Tachycardia (2) Thoracic Diseases (2) Thrombocytopenia (2) Toxemia (2) Trauma and Stressor Related Disorders (2) Tuberculosis (2) Urinary Bladder, Overactive (2) Urinary Tract Infections (2) Uterine Cervical Neoplasms (2) Uveitis (2) Vision Disorders (2) Vision, Low (2) Yellow Fever (2) Abruptio Placentae (1) Acalculous Cholecystitis (1) Adenocarcinoma (1) Adjustment Disorders (1) Adrenal Insufficiency (1) Alcohol Drinking in College (1) Alcohol-Related Disorders (1) Alcoholic Intoxication (1) Alveolitis, Extrinsic Allergic (1) Amblyopia (1) Anemia, Aplastic (1) Angina, Stable (1) Anorexia (1) Anorexia Nervosa (1) Aortic Valve Stenosis (1) Apnea (1) Arthritis, Juvenile (1) Aspergillosis (1) Aspergillosis, Allergic Bronchopulmonary (1) Asphyxia Neonatorum (1) Asthenopia (1) Atrioventricular Block (1) Atrophy (1) Autonomic Nervous System Diseases (1) Back Pain (1) Bacteremia (1) Barotrauma (1) Birth Weight (1) Blister (1) Body Weight Changes (1) Bone Diseases, Metabolic (1) Bradycardia (1) Brain Concussion (1) Breast Cancer Lymphedema (1) Bronchial Diseases (1) Bronchiolitis (1) Bronchitis (1) Bronchitis, Chronic (1) Bronchopulmonary Dysplasia (1) Brucellosis (1) Bulimia (1) Calculi (1) Carcinoma, Hepatocellular (1) Carcinoma, Ovarian Epithelial (1) Carcinoma, Small Cell (1) Carcinoma, Squamous Cell (1) Cardiovascular Abnormalities (1) Cataract (1) Celiac Disease (1) Cellulitis (1) Cerebral Hemorrhage (1) Cerebral Palsy (1) Cerebrovascular Disorders (1) Chest Pain (1) Chlamydia Infections (1) Cholangiocarcinoma (1) Cholangitis (1) Cholecystitis (1) Cholecystitis, Acute (1) Chronic Traumatic Encephalopathy (1) Clostridium Infections (1) (1) Colonic Diseases (1) Communication Disorders (1) Compulsive Behavior (1) Consciousness Disorders (1) Constipation (1) Constriction, Pathologic (1) Conversion Disorder (1) (1) (1) Coronary Artery (1) Coronary Stenosis (1) (1) Cough (1) Coxsackievirus Infections (1) Cryopyrin-Associated Periodic Syndromes (1) Deafness (1) Death, Sudden, Cardiac (1) Dental Calculus (1) Dental Plaque (1) Depressi (1) Depressive Disorder, Treatment-Resistant (1) DiGeorge Syndrome (1) Diabetic Nephropathies (1) Diabetic Neuropathies (1) Diphtheria (1) (1) Down Syndrome (1) Dyspareunia (1) Emergence Delirium (1) Encephalitis (1) Endocarditis (1) Endophthalmitis (1) Endotoxemia (1) Enuresis (1) Epilepsy (1) Esophageal and Gastric Varices (1) Esophagitis, Peptic (1) Eye Diseases (1) Eye Infections (1) Fabry Disease (1) Facial Pain (1) Familial Mediterranean Fever (1) Fatty Liver (1) (1) Femoral Neck Fractures (1) Fetal Growth Retardation (1) Fetal Membranes, Premature Rupture (1) Fever of Unknown Origin (1) Fistula (1) Food Hypersensitivity (1) Fractures, Closed (1) Fractures, Stress (1) Gait Disorders, Neurologic (1) Genetic Diseases, Inborn (1) Genetic Predisposition to Disease (1) Gestational Weight Gain (1) Gingivitis, Necrotizing Ulcerative (1) Gout (1) (1) Headache Disorders, Secondary (1) Hearing Loss (1) Hearing Loss, Conductive (1) Heart Failure, Diastolic (1) Heart Murmurs (1) Helminthiasis (1) Hematoma (1) Hematoma, Subdural (1) Hematoma, Subdural, Chronic (1) Hemoglobinopathies (1) Hepatitis (1) Hepatitis A (1) Hepatitis C (1) Hepatitis, Alcoholic (1) Hereditary Autoinflammatory Diseases (1) Herpes Labialis (1) Herpes Zoster (1) Hodgkin Disease (1) Hyaline Membrane Disease (1) Hyperaldosteronism (1) Hypercapnia (1) Hyperphosphatemia (1) Hyperplasia (1) Hypersensitivity, Immediate (1) Hypertension, Pregnancy-Induced (1) Hypokalemia (1) Hyponatremia (1) Hypoparathyroidism (1) Hypotension (1) Iatrogenic Disease (1) Infant, Newborn, Diseases (1) Infec (1) Infecti (1) Infertility, Female (1) Infertility, Male (1) Intellectual Disability (1) Intestinal Atresia (1) Intracranial Hypertension (1) Intracranial Thrombosis (1) Jaundice, Obstructive (1) Joint Diseases (1) Keratoconjunctivitis (1) Keratosis (1) Keratosis, Actinic (1) Leishmaniasis (1) Leukemia, Lymphocytic, Chronic, B-Cell (1) Leukemia, Myeloid (1) Leukemia, Myelomonocytic, Acute (1) Leukemia, Myelomonocytic, Chronic (1) Liver Cirrhosis, Biliary (1) Liver Failure (1) Low Back Pain (1) Lung (1) Lyme Disease (1) Lymphedema (1) Lymphocytosis (1) Lymphoma, B-Cell (1) Lymphoma, Mantle-Cell (1) Macrophage Activation Syndrome (1) Malaria (1) Maternal Death (1) Maxillofacial Injuries (1) Memory Disorders (1) Meningitis (1) Meningitis, Meningococcal (1) Menorrhagia (1) Menstruation Disturbances (1) Microvascular Rarefaction (1) Mitochondrial Diseases (1) Molluscum Contagiosum (1) Monoclonal Gammopathy of Undetermined Significance (1) Mouth Diseases (1) Mouth, Edentulous (1) Movement Disorders (1) Mucositis (1) Multiple Chronic Conditions (1) Muscle Spasticity (1) Muscular Atrophy (1) Muscular Dystrophy, Duchenne (1) Myalgia (1) Myocardial Reperfusion Injury (1) Myofascial Pain Syndromes (1) Needlestick Injuries (1) Neonatal Sepsis (1) Neoplastic Cells, Circulating (1) Nephritis (1) Neurobehavioral Manifestations (1) Neurocognitive Disorders (1) Neuromyelitis Optica (1) Non-alcoholic Fatty Liver Disease (1) Obsessive Behavior (1) Olfactory Nerve Injuries (1) Orbital Cellulitis (1) Osteoarthritis, Hip (1) Osteochondritis (1) Osteomyelitis (1) Otitis Media with Effusion (1) Overweig (1) Pain (1) Pain, Procedural (1) Pancreatitis (1) Paraproteinemias (1) Paresis (1) Peanut Hypersensitivity (1) Perinatal Death (1) Periodontal Diseases (1) Peripheral Nervous System Diseases (1) Peritoneal Neoplasms (1) Pharyngeal Diseases (1) Pleuropneumonia (1) (1) (1) Pneumonia, Bacterial (1) Pneumonia, V (1) Pre-Eclampsia (1) Pregnancy in Diabetics (1) Preleukemia (1) Primary Dysautonomias (1) Prostatic Hyperplasia (1) Protein-Energy Malnutrition (1) Psychophysiologic Disorders (1) Puerperal Infection (1) Pulmonary Alveolar Proteinosis (1) Pulmonary Aspergillosis (1) Pulmonary Atelectasis (1) Pulmonary Eosinophilia (1) Radiculopathy (1) Rectal Neoplasms (1) Reperfusion Injury (1) (1) (1) Respiratory Distress Sy (1) Respiratory Hypersensitivity (1) Retinal Vein Occlusion (1) Rupture (1) Sarcoidosis, Pulmonary (1) Sarcopenia (1) Schizophrenia Spectrum and Other Psychotic Disorders (1) (1) Scleroderma, Localized (1) Scleroderma, Systemic (1) Self-Injurious Behavior (1) Severe Acute Respiratory Syn (1) Sexually Transmitted Diseases (1) Sexually Transmitted Diseases, Bacterial (1) Shock, Cardiogenic (1) Short Bowel Syndrome (1) Signs and Symptoms, Digestive (1) Skin Abnormalities (1) Skin Diseases (1) Skin Manifestations (1) Skin Neoplasms (1) Skull Fractures (1) Sleep Apnea, Central (1) Soft Tissue Neoplasms (1) Somatoform Disorders (1) Spinal Stenosis (1) Spondylarthritis (1) Spondylolisthesis (1) Status Epilepticus (1) Stillbirth (1) Stomatitis (1) Str (1) Stress Disorders, Traumatic, Acute (1) Subarachnoid Hemorrhage (1) Superinfection (1) Syncope (1) Syncope, Vasovagal (1) Tachycardia, Sinus (1) Tachycardia, Ventricular (1) Temporomandibular Joint Disorders (1) Temporomandibular Joint Dy (1) Temporomandibular Joint Dysfunction Syndrome (1) Thalassemia (1) Thrombophlebitis (1) Torsades de Pointes (1) Tourette Syndrome (1) Trauma, Nervous System (1) Trichuriasis (1) Tuberculosis, Pulmonary (1) Ulce (1) Urinary Bladder, Underactive (1) Urinary Incontinence (1) Urinary Retention (1) Urologic Diseases (1) Urticaria (1) Uterine Neoplasms (1) Vaginal Neoplasms (1) Ventricular Dysfunction, Right (1) Virus Dis (1) Von Willebrand Diseases (1) Vulvar Neoplasms (1) Weight Gain (1) Xerostomia (1) beta-Thalassemia (1)

D003704: Dementia

Developed by Shray Alag, The Harker School
Sections: Correlations, Clinical Trials, and HPO

Correlations computed by analyzing all clinical trials.

Navigate: Clinical Trials and HPO


Correlated Drug Terms (18)


Name (Synonyms) Correlation
drug1013 Deferoxamine Wiki 0.53
drug3985 nCapp, a cell phone-based auto-diagnosis system Wiki 0.38
drug3015 SPIRIT-remote Wiki 0.38
Name (Synonyms) Correlation
drug583 CAPABLE Transitions Wiki 0.38
drug999 Data collection and rhinopharyngeal swab Wiki 0.38
drug252 Anthocyanins Wiki 0.38
drug1491 Home Health Agency Care Wiki 0.38
drug3992 newborns from covid 19 positive mothers Wiki 0.38
drug2424 Paramedic Coaching Wiki 0.38
drug3401 Telephone interview Wiki 0.38
drug3014 SPIRIT-in person Wiki 0.38
drug1796 LIVE Wiki 0.38
drug823 Cognitive Stimulation Wiki 0.38
drug3990 nebulised recombinant tissue-Plasminogen Activator (rt-PA) Wiki 0.38
drug3492 Tocilizumab Injection Wiki 0.27
drug3607 Usual care Wiki 0.22
drug3993 no intervention Wiki 0.13
drug2505 Placebo Wiki 0.02

Correlated MeSH Terms (5)


Name (Synonyms) Correlation
D019965 Neurocognitive Disorders NIH 0.38
D003331 Coronary Artery NIH 0.38
D060825 Cognitive Dysfunction NIH 0.33
Name (Synonyms) Correlation
D003324 Coronary Artery Disease NIH 0.14
D007249 Inflammation NIH 0.07

Correlated HPO Terms (3)


Name (Synonyms) Correlation
HP:0000726 Dementia HPO 1.00
HP:0001268 Mental deterioration HPO 0.34
HP:0001677 Coronary artery atherosclerosis HPO 0.15

Clinical Trials

Navigate: Correlations   HPO

There are 7 clinical trials


1 Preparation for End-of-Life Decision Making in Mild Dementia

The proposed study will adapt and pilot test an efficacious advance care planning interventions, SPIRIT (Sharing Patient's Illness Representations to Increase Trust), with patients with mild dementia and their surrogates to promote open, honest discussions while such discussions about end-of-life care are possible. The study includes two phases: Phase I to adapt, pretest, and refine SPIRIT, and Phase II to pilot test the refined SPIRIT to formally evaluate its feasibility, acceptability, and preliminary efficacy. The final products will be the modified SPIRIT intervention that improves dementia patient and surrogate outcomes, and standardized intervention manuals, including the SPIRIT Interview Guide, fidelity assessment, and training materials. Patient and surrogate decision maker dyads will participate in a single SPIRIT session and will then have a follow up phone call 2-3 days later. One year after the SPIRIT session some surrogates will be contacted to provide additional feedback about the intervention.

NCT03311711
Conditions
  1. Dementia
Interventions
  1. Behavioral: SPIRIT-in person
  2. Behavioral: SPIRIT-remote
  3. Behavioral: Usual care
MeSH:Dementia
HPO:Dementia

Primary Outcomes

Description: Dyad congruence will be assessed using the Goals-of-Care Tool which has been modified to include two scenarios relevant to the context of dementia. There are three response options: "The goals of care should focus on delaying my death no matter what, and thus I want to continue life-sustaining treatment", "The goals of care should focus on my comfort and peace, and thus I do not want life-sustaining treatment", and "I am not sure". Patients and surrogates complete this tool independently and their responses are then compared to determine dyad congruence (either congruent in both scenarios or incongruent). If both members of the dyad endorse "I am not sure", they are considered incongruent.

Measure: Change in dyad congruence among Phase II participants

Time: Baseline, follow up phone call (2-3 days post-intervention)

Description: Surrogate decision-making confidence will be measured using the 5-item Decision Making Confidence (DMC) scale. DMC assesses a surrogate's confidence in knowing the patient's wishes, ability to make treatment decisions even in a highly stressful situation, ability to seek information about risks and benefits of medical choices, ability to handle unwanted pressure from others, and ability to communicate with providers about the patient's wishes. Surrogates indicate how confident they are about making medical decisions, if the patient becomes unable to make their own decisions, by their level of agreement with statements along a scale of (0) "not confident at all" to (4) "Very confident". Total scores range from 0 - 20, with higher scores indicating greater confidence.

Measure: Change in Surrogate's Decision Making Confidence (DMC) scale score among Phase II participants

Time: Baseline, follow up phone call (2-3 days post-intervention)

Description: The Overall Preparedness Scale for end-of-life decision making for surrogates is a 21-item investigator-developed measure. The measure assesses the level of preparedness for end-of-life decision making in the cognitive, emotional, and behavioral dimensions on a 4-point scale (1=strongly disagree to 4=strongly agree). Total scores range from 21 to 84, with higher scores indicating higher levels of preparedness.

Measure: Change in Surrogate's Overall Preparedness Scale

Time: Baseline, follow up phone call (2-3 days post-intervention)

Secondary Outcomes

Description: Medical records will be reviewed to determine if the patient completed an advance directive (a medical power of attorney or living will) by 12 months post-intervention. If there is no documentation, the surrogate will be contacted to get confirmation on the status of the Advance Directive.

Measure: Completion of Advance Directives among Phase I participants

Time: 12 months post-intervention

Description: Medical records will be reviewed to determine if the patient completed an advance directive (a medical power of attorney or living will) by 12 months post-intervention. If there is no documentation, the surrogate will be contacted to get confirmation on the status of the Advance Directive.

Measure: Completion of Advance Directives among Phase II participants

Time: 12 months post-intervention

Description: The Overall Preparedness Scale for end-of-life decision making for patients is a 20-item investigator-developed measure. The measure assesses the level of preparedness for end-of-life decision making in the cognitive, emotional, and behavioral dimensions on a 4-point scale (1=strongly disagree to 4=strongly agree). Total scores range from 20 to 80, with higher scores indicating higher levels of preparedness.

Measure: Change in Patient's Overall Preparedness Scale

Time: Baseline, follow up phone call (2-3 days post-intervention)
2 A Randomized, 24-week Parallel-group Placebo-controlled Multicenter (Phase 2) Study of Anthocyanins in People at Risk for Dementia

The aim of this project is to study the safety and efficacy of anthocyanins in improving key dementia-related mechanisms and cognitive functioning in older people at risk for dementia. Secondary analyses will include a variety of biological measures, including biochemistry, imaging and cardiovascular measures.

NCT03419039
Conditions
  1. Dementia
  2. Inflammation
  3. Mild Cognitive Impairment
  4. Coronary Artery Disease
Interventions
  1. Dietary Supplement: Anthocyanins
  2. Dietary Supplement: Placebo
MeSH:Dementia Coronary Artery Coronary Artery Disease Inflammation Cognitive Dysfunction
HPO:Cognitive impairment Coronary artery atherosclerosis Dementia Mental deterioration

Primary Outcomes

Description: A composite measure from the CogTrack battery

Measure: Quality of episodic memory.

Time: Baseline to 24 weeks

Secondary Outcomes

Description: CogTrack evaluates attentional intensity index, sustained intensity index, cognitive reaction time, attentional fluctuation index, quality of working memory, quality of episodic memory and speed of memory retrieval.

Measure: Secondary endpoints from CogTrack

Time: Baseline to 24 weeks

Description: Lipid profile, fatty acids, cytokines ( among others: IL-1, IL-2, IL-6, TNF-a), plasma antoxidant status and vitamins (lipid peroxidation markers, vitamins E, C, A, total plasma antioxidant capacity, glutathion)., carinthine, blood glucose, HbA1c, anthocyanins and metabolites, mapping of a-beta degradation products.

Measure: Blood outcome analysis

Time: Baseline to 24 weeks

Description: Flow-mediated dilation (FMD), Cardiac-ankle vascular index (CAVI), photoplethysmogram (PPG).

Measure: Cardiovascular parameters

Time: Baseline to 24 weeks

Description: Microbiota

Measure: Fecal analysis

Time: Baseline to 24 weeks

Description: kyrinin

Measure: Urine analysis

Time: Baseline to 24 weeks

Description: anthocyanin metabolites

Measure: CSF measurements

Time: Baseline to 24 weeks

Description: Diagnosing and follow-up of cerebrovascular disease

Measure: MR-imaging/CT

Time: Baseline to 24 weeks
3 LIVE@Home.Path: a Mixed Method, Stepped Wedge and Randomized Controlled Trial Innovating the Clinical Pathway for Home-dwelling Persons With Dementia and Their Families

This study aims at developing, implementing and evaluating a complex intervention involving Learning, Innovation, Volunteers and Empowerment for home dwelling persons with dementia and their caregivers. The investigators hypothesise that a successfully implemented intervention will reduce caregivers burden and be cost-effective.

NCT04043364
Conditions
  1. Dementia
  2. Home-dwelling
  3. Caregiver
Interventions
  1. Behavioral: LIVE
MeSH:Dementia
HPO:Dementia

Primary Outcomes

Description: RUD:A validated tool for assessment of time use for cost effectiveness analyses, measuring total time use in hours/day for different activities, numbers of contact points with care professionals and use of medications, high time use, many contacts and many medications indicates high resource use

Measure: Resource Utilization in Dementia

Time: up to 24 months follow up, assesment every 6 months

Description: RSS: measuring caregiver distress, 15 items ranging from 0-4, high score indicates high burden

Measure: Relative stress scale

Time: up to 24 months follow up, assessment every 6 months

Secondary Outcomes

Description: I-ADL scale assessing instrumental activities such as use of telephone, economy, household, public transport and shopping, range from 8-31, higher score indicates poorer functioning

Measure: Activities of daily living, instrumental

Time: 24 months follow up, assesment every 6 months

Description: CSDD: Cornell scale for depression in dementia, range 0-38, high score indicates high symptom load

Measure: Depression and mood

Time: 24 months follow up, assesment every 6 months

Description: CMAI: Cohen-Mansfield Agitation Inventory, 29 items assessing the frequency of agitated behaviour, range 29-203, high score indicates higher severity

Measure: Agitation

Time: 24 months follow up, assesment every 6 months

Description: NPI: presence, severity and burden of depression, anxiety, psychosis and motor disturbances, range from 0-144, high score indicates frequent, severe and burdensome symptoms

Measure: Neuropsychiatric symptoms

Time: 24 months follow up, assesment every 6 months

Description: Falls, disappearances outdoor, admissions to acute wards, fire hazard

Measure: Adverse events

Time: 24 months follow up, assesment every 6 months

Description: number of technical aids, cognitive intervention devices and assisted-living systems

Measure: Use of assistive technology

Time: 24 months follow up, assesment every 6 months

Description: number of participants with contact with a volunteer, number of hours spent with volunteer

Measure: Use of volunteers

Time: 24 months follow up, assesment every 6 months

Description: P-ADL, assessing personal activities such as toileting, grooming, dressing, transfer and eating, scale range 6-30, higher score indicates poorer personal functioning

Measure: Activities of daily living, personal

Time: 24 months follow up, assesment every 6 months

Description: EQ-5D-5L, Descriptive measure of health related quality of life comprising 5 Dimensions With 5 Levels each, scores can be converted to a single summary index number

Measure: Quality of Life

Time: 24 months follow up, assesment every 6 months

Description: EQ-5D, Descriptive measure of quality of life rated on a VAS scale range 0-100, high score indicates good health

Measure: Quality of Life VAS scale

Time: 24 months follow up, assesment every 6 months

Description: QoL-AD: Quality of life in Alzheimer dementia, 13 items likert scale, range from 13-52 points, high score indicates high quality of life

Measure: Quality of Life

Time: 24 months follow up, assesment every 6 months

Description: number of hours spent with a volunteer

Measure: Use of volunteers

Time: 24 months follow up, assesment every 6 months

Description: Clinical global impression of change, to quantify and track patient progress and treatment response on a scale from 1 to 7, at which 7 indicates substantial worsening.

Measure: Change achieving

Time: at the start of intervention, and every 6 months

Description: GDS: Geriatric depression scale, 30 items rated yeas or no, high score indicates high burden

Measure: Caregiver depression

Time: 24 months follow up, assesment every 6 months

Description: GMHR: General medical health rating scale, 4 point likert scale, range from 1-4, high score indicates high comorbidity burden

Measure: Comorbidity

Time: 24 months follow up, assesment every 6 months

Description: MOBID-2: assesses the intensity of pain based on interpretation of pain related behaviour, range from 0-10, high score indicates high pain intensity

Measure: Pain in dementia

Time: 24 months follow up, assesment every 6 months

Description: IQ CODE: Proxy rater instrument for assessment of change in cognitive performance the last 10 years, range 16-80, high score indicates great decline

Measure: Change in cognitive performance

Time: Baseline

Description: Self and proxy reported use of medications, both regular and on demand

Measure: Medication use

Time: At the start of the intervention, and every 6 onth follow up

Description: Participation in educational programes, both for persons with dementia and for caregivers.

Measure: Participation in educational programs

Time: 24 months follow up, assessment every 6 months

Other Outcomes

Description: Caregivers perception of risk of contamination With Sars-Cov-10

Measure: COVID-19: risk perception

Time: month 6 to month 12 (during COVID-19 lock down in Norway)

Description: Change in services and contact due to restrictions of COVID-19

Measure: COVID-19: restrictions

Time: month 6 to month 12 (during COVID-19 lock down in Norway)

Description: Caregivers perception of caregiver burden during COVID-19

Measure: COVID-19: caregiver burden

Time: month 6 to month 12 (during COVID-19 lock down in Norway)

Description: NPI: change in presence, severity and burden of depression, anxiety, psychosis and motor disturbances

Measure: COVID-19: neuropsychiatric symptoms

Time: month 6 to month 12 (during COVID-19 lock down in Norway)

Description: CSDD: Change in cornell scale for depression in dementia.

Measure: COVID-19: depression and mood

Time: month 6 to month 12 (during COVID-19 lock down in Norway)
4 Community Paramedic Coaching Program for Caregivers and People With Dementia (CP3D)

This pilot study is designed to evaluate the potential effectiveness of the implementation strategy and intervention delivery model of a community paramedic coaching program for caregivers of persons with dementia, in direct coordination with the participant and caregiver's primary health care team. Specifically, the acceptability, appropriateness, and feasibility of the program will be assessed, collecting data from all implementation stakeholders at baseline, 13 weeks, 25 weeks, and post-intervention (~50 weeks) using quantitative survey instruments and qualitative interviews.

NCT04239924
Conditions
  1. Dementia
Interventions
  1. Behavioral: Paramedic Coaching
MeSH:Dementia
HPO:Dementia

Primary Outcomes

Description: As determined by abstracting the medical records, the investigators are testing the hypothesis that the number of visits to the Emergency Department is lower than commonly reported in the literature for persons with dementia.

Measure: Number of Visits to the Emergency Department by the Person with Dementia

Time: up to 24 months

Description: As determined by abstracting the medical records, the investigators are testing the hypothesis that the number of visits to the Emergency Department is lower than commonly reported in the literature for average older adults.

Measure: Number of Visits to the Emergency Department by the Caregiver of the Person with Dementia

Time: up to 24 months

Description: The intervention will be deemed feasible if at least 75% of the intended coaching phone calls are completed. The minimum number of coaching calls is 3, additional calls will be scheduled opposite weeks of home visits as needed.

Measure: Feasibility: Proportion of Coaching Phone Calls Completed

Time: up to 12 months

Description: The intervention will be deemed feasible if at least 75% of the intended home visits are completed. The minimum number of intended home visits is 9.

Measure: Feasibility: Proportion of Coaching Home Visits Completed

Time: up to 12 months

Secondary Outcomes

Description: The Zarit Burden Interview measures caregiver burden. This is a 12-item survey with a total possible range of scores from 0-48, where higher scores indicate increased burden. The investigators hypothesize the score will decrease as a result of the intervention.

Measure: Change in Zarit Burden Interview (ZBI-12) Score

Time: First home visit (~ week 1), week 13, week 25, and last home visit (~up to week 50)

Description: The GAD-7 is a 7-item survey that measures anxiety symptom severity. The total possible range of scores is 0-21, where higher scores indicate increased symptom severity. The investigators hypothesize the score will decrease as a result of the intervention.

Measure: Change in Generalized Anxiety Disorder (GAD-7) Score

Time: Baseline, week 13, week 25, week 50

Description: The CESD-10 is a general measure of depression frequently used in caregiver studies. It is a 10-item survey with a total possible range of scores of 0-30 where higher scores indicate increased depression. The investigators hypothesize the score will decrease as a result of the intervention.

Measure: Change in Center for Epidemiologic Studies Depression Scale (CESD-10)

Time: First home visit (~ week 1), week 13, week 25, and last home visit (~up to week 50)

Description: The RCSS is a 6-item survey used to measure the positive aspects of caring. The range of total possible scores is 6-30 where higher scores indicate increased caregiver satisfaction. The investigators hypothesize the score will increase as a result of the intervention.

Measure: Change in Revised Caregiving Satisfaction Scale (RCSS)

Time: Baseline, week 13, week 25, week 50

Description: The revised scale for caregiving self-efficacy measures three domains: obtaining respite, responding to disruptive patient behaviors, and controlling upsetting thoughts. It is a 15-item scale with a total possible range of scores between 0-100, where higher scores are better. The investigators hypothesize the score will increase as a result of the intervention.

Measure: Change in Revised Scale for Caregiving Self-Efficacy

Time: First home visit (~ week 1) and last home visit (~up to week 50)

Description: WFC is measured for the caregiver. It is a 6-item survey with a total possible range of scores between 6-30 with higher scores indicating lesser work-family conflict. The investigators hypothesize the score will increase as a result of the intervention.

Measure: Change in Work-Family Conflict Scale (WFC)

Time: First home visit (~ week 1) and last home visit (~up to week 50)

Description: C-DEMQOL is measured for the caregiver. The investigators will be asking 18 of the questions from the scale to understand the quality of life the caregivers experience. Scores can range from 18-90, with a higher score reflecting a higher quality of life.

Measure: Change in Caregiver Quality of Life (C-DEMQOL) Score

Time: Baseline and 62 weeks (12 weeks post completion)

Description: DKAS is measured for the caregiver. It is a 25 item true-false survey of facts about dementia. Scoring is by measuring the proportion of questions answered correctly.

Measure: Change in Knowledge of Dementia (DKAS) Score

Time: Baseline and 62 weeks (12 weeks post completion)

Description: As determined by abstracting the medical records, the investigators are characterizing the number of contacts with outpatient clinics for persons with dementia.

Measure: Clinic Utilization by Persons with Dementia

Time: up to 24 months

Description: As determined by abstracting the medical records, the investigators are characterizing the number of contacts with outpatient clinics for caregivers of persons with dementia.

Measure: Clinic Utilization by Caregivers of Persons with Dementia

Time: up to 24 months

Description: Assesses caregivers perception of communication with health care team and extent to which the team considers their capacity and preferences in decision making. This measure consists of 12 questions, with scores ranging from 12-60, where higher scores indicate increased communication with the health care team.

Measure: Change in Caregiver Perceptions About Communication With Clinical Team Members (CAPACITY) Measure

Time: Baseline and 62 weeks (12 weeks post completion)
5 Cognitive Outcomes During COVID-19 confiNemeNt in Elderly and Their Caregivers Using Technologies for DEMentia

Coronavirus disease 2019 has forced worldwide the implementation of unprecedented restrictions to control its rapid spread and mitigate its impact. The Spanish government has enforced social distancing, quarantine and home confinement. This restriction of daily life activities and separation from loved ones may lead to social isolation and loneliness with health-related consequences in community-dwelling older adults with mild cognitive impairment or mild dementia and their caregivers. Additionally, an inadequate access to healthcare and social support services may aggravate chronic conditions. Technology home-based interventions emerge for combating social isolation and loneliness preventing the risk of viral exposure. The aim of this multicentre cohort study is to explore, analyze and determine the impact of social isolation on: 1) cognition, quality of life, mood, technophilia and perceived stress of community-dwelling older adults with mild cognitive impairment or mild dementia, and on caregiver burden; 2) health and social care services access and utilization, and 3) cognitive, social and entertainment use of ICTs. This study will be conducted in two Spanish regions Andalucía (Málaga) and Cataluña (Tarrasa). In total 414 dyads, consisting of a person with mild cognitive impairment or mild dementia (PMCI/MD) and their informal caregiver will be contacted by telephone. Potential respondents will be participants of the SMART 4 MD (N=2921), TV-AssistDem (N=100) and INFINITy (N=23) clinical trials. The change in means in the variables will be analyzed comparing baseline results in the previous studies with those during and after confinement using the ANOVA test of repeated measures or the non-parametric Friedman test if appropriate. The performance of a multivariate analysis of variance (ANCOVA) to introduce possible covariates will also be contemplated. A 95% confidence level will be used.

NCT04385797
Conditions
  1. Mild Cognitive Impairment
  2. Dementia
Interventions
  1. Other: Telephone interview
MeSH:Dementia Cognitive Dysfunction
HPO:Cognitive impairment Dementia Mental deterioration

Primary Outcomes

Description: The Mini-Mental State Examination (MMSE) (23) will be used to assess the cognitive function of the PMCI/MD. The most common cutoff scores for cognitive impairment and dementia are ranging 23 to 27 over 30. As telephone call interviewing will be the safest means to communicate with the PMCI/MD during and after the COVID-19 pandemic the 22 items telephone version of the MMSE will be used (24). All points of the MMSE can be covered in the telephone version except the last section assessing language and motor skills. In the phone version, we will ask the subject to repeat a phrase and name one item (For example: "Tell me, what is the name of the object you are using to talk to me?"). However, a second item will be not be named, nor will be the person be asked to follow a three-stage command, read and obey a sentence, write a sentence, or copy an intersecting pentagon as in the original version.

Measure: Change on cognitive function in people with mild cognitive impairment or mild dementia prior to, during and after confinement.

Time: Through study completion, an average of 6 months

Secondary Outcomes

Description: The Quality of Life-Alzheimer's Disease Scale (QoL-AD) (19-22) is an instrument specifically designed to measure QoL in PMCI/MD from the perspective of both the patient and the informal caregiver. It is a 13-item measure, which includes assessments of the person´s relationships with friends and family, financial situation, physical condition, mood, memory, and an overall assessment of life quality. Response are 4-point multiple choice options (1 = poor, 2= fair, 3= good, 4 = excellent). Scale scores range from 13 to 52, with higher scores indicating greater quality of life. When cognitive function may be compromised, informal caregivers will complete the QoL-AD, on behalf of the PMCI/MD.

Measure: Change on quality of life in Alzheimer´s Disease in people with mild cognitive impairment or mild dementia prior to, during and after confinement.

Time: Through study completion, an average of 6 months

Description: The European Quality of Life 5 Dimensions 3 Levels (EuroQoL-5D-3L) is a standardized generic instrument consisting of a descriptive system and a visual analogue scale (VAS). The descriptive system comprises 5 dimensions covering mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 3 levels: no problems, moderate problems and extreme problems. A 1-digit number expresses the level selected for that dimension. The digits can be combined into a 5-digit number that describes the patient's health state. The VAS records the patient's self-rated health on a vertical scale, where the endpoints are 100 = 'The best health you can imagine' and 0 = 'The worst health you can imagine'. EuroQoL-5D-3L has been shown to correlate well with QoL-AD, indicating that using both measures side-by-side is compatible.

Measure: Change on quality of life in people with mild cognitive impairment or mild dementia prior to, during and after confinement.

Time: Through study completion, an average of 6 months

Description: The Short Form of the Geriatric Depression Scale (GDS) (25) will be used to assess mood. Of the 15 items, 10 indicate depression when answered positively, while the rest (1, 5, 7, 11, 13) when answered negatively. Scores of 0-4 are considered normal, 5-8 indicate mild depression, 9-11 moderate depression, and 12-15 severe depression.

Measure: Change on mood in people with mild cognitive impairment or mild dementia prior to, during and after confinement.

Time: Through study completion, an average of 6 months

Description: The Instrument for Measuring Older People's Attitudes Toward Technology (TechPH) measures older people's attitudes and enthusiasm for health technology (26). This instrument refers to technophilia as a person's enthusiasm for and positive feelings toward their technology use and absence of the fears and doubts some older people could have about their ability to manage using new technology. The six items of the instrument measure two factors of technophilia: 3 items concerning techEnthusiasm and 3 items techAnxiety. Response are constructed with a five-point Likert scale questionnaire, ranging from 1 (fully disagree) to 5 (fully agree).

Measure: Change on technophilia in people with mild cognitive impairment or mild dementia prior to, during and after confinement.

Time: Through study completion, an average of 6 months

Description: The Perceived Stress Scale (PSS) measures the degree to which situations in one's life are appraised as stressful. The scale has 10 questions regarding feelings and thoughts during the last month and are rated according to frecuency 0 = Never 1 = Almost Never 2 = Sometimes 3 = Fairly Often 4 = Very Often. PSS scores are obtained by reversing responses (e.g., 0 = 4, 1 = 3, 2 = 2, 3 = 1 & 4 = 0) to the four positively stated items (items 4, 5, 7, & 8) and then summing across all scale items

Measure: Change on perceived stress in people with mild cognitive impairment or mild dementia during and after confinement.

Time: Through study completion, an average of 6 months

Description: The Zarit Burden Interview (ZBI-12) is a 12-item scale with each answer chosen from a 5-point Likert scale (Nearly always=4, Quite frequently=3, Sometimes=2, Rarely=1, Never=0). It is a shortened version of the original scale, was developed specifically for informal caregivers of PMCI/MD and covers issues such as caregiver stress and the degree to which caring is affecting their health and social life. Total score range 0 to 48 (0-10= no to mild burden, 10-20= mild to moderate burden >20= high burden).

Measure: Change on caregiver burden prior to, during and after confinement.

Time: Through study completion, an average of 6 months

Description: The Client Service Receipt Inventory (CSRI) (32,33) scale will be used to evaluate the service utilization. This scale is an internationally used method for gathering data on service utilization and other domains relevant for economic analysis of mental health care. It has five sections: background client information, accommodation and living situation, employment history, earnings and benefits, a record of services usually used and information about informal caregiver support. The sections assessed will be consultations, admissions and visits, grouped into subsections according to hospital, specialist, primary or home care. Treatment related to hospital admissions or illness exacerbation will also be assessed. It´s adaptability ensures it is compatible with the research aims, context, participants' likely circumstances, and the quantity and precision of information required.

Measure: Change on healthcare and social support services access prior to, during and after confinement.

Time: Through study completion, an average of 6 months

Description: Use of ICTs (SmartPhone, Tablet, Computer, Smart-TV, or other) to contact healthcare and social support services, to stimulate cognition, to facilitate social connectedness (telephone call, video call, texting...), to access COVID-19 information and to enable entertainment.

Measure: Change from health, cognitive, social, informative and entertainment related uses of ICT during and after confinement.

Time: Through study completion, an average of 6 months
6 Care at 360º: A Long-term Individual Cognitive Stimulation Program for Older Adults With Neurocognitive Disorders, Non-Institutionalized and Socially Vulnerable

The aim of the intervention proposed in the present study is to assess the effect of a cognitive stimulation (CS) intervention program in an individual and long-term format, for non-institutionalized elderly people with neurocognitive disorders and in a situation of social vulnerability. Specifically, to test the effectiveness of CS on the global cognitive state, on mood state, on quality of life and on functional state. The program will be composed by 50 sessions, including three of assessment sessions (pre, intra and post-intervention). Each session will have a duration of 45 minutes with a weekly frequency. Control group participants will maintain their treatment as usual.

NCT04417751
Conditions
  1. Neurocognitive Disorders
  2. Dementia
  3. Cognitive Impairment
  4. Cognitive Decline
  5. Cognitive Dysfunction
  6. Social Behavior
Interventions
  1. Behavioral: Cognitive Stimulation
MeSH:Dementia Cognitive Dysfunction Neurocognitive Disorders
HPO:Cognitive impairment Dementia Mental deterioration

Primary Outcomes

Description: Significant statistic improvement in the participant's test scores between pre-intervention, intra-intervention and postintervention assessments. Mini-Mental State Examination is a brief screening test for cognitive function. Assesses 6 cognitive functions: orientation, registration, attention and calculation, recall, language and visuoconstructive ability. Global score ranges from 0-30 points, higher scores indicate better cognitive function.

Measure: Cognitive state evaluated through Mini-Mental State Examination

Time: Pre-intervention

Description: Significant statistic improvement in the participant's test scores between pre-intervention, intra-intervention and postintervention assessments. Mini-Mental State Examination is a brief screening test for cognitive function. Assesses 6 cognitive functions: orientation, registration, attention and calculation, recall, language and visuoconstructive ability. Global score ranges from 0-30 points, higher scores indicate better cognitive function.

Measure: Change in cognitive state evaluated through Mini-Mental State Examination

Time: 6 months after the beginning of the intervention

Description: Significant statistic improvement in the participant's test scores between pre-intervention, intra-intervention and postintervention assessments. Mini-Mental State Examination is a brief screening test for cognitive function. Assesses 6 cognitive functions: orientation, registration, attention and calculation, recall, language and visuoconstructive ability. Global score ranges from 0-30 points, higher scores indicate better cognitive function.

Measure: Change in cognitive state evaluated through Mini-Mental State Examination

Time: 12 months after the beginning of the intervention

Description: It's a 32-item mild cognitive impairment screening instrument that assesses eight cognitive functions: visuospatial/executive, naming, memory, attention, language, abstraction, delayed recall and orientation. Montreal Cognitive Assessment score is calculated by adding the points of the tasks successfully completed, and it ranges from 0 to 30 points, being that higher scores indicate better cognitive performance.

Measure: Cognitive performance evaluated through Montreal Cognitive Assessment

Time: Pre-intervention

Description: It's a 32-item mild cognitive impairment screening instrument that assesses eight cognitive functions: visuospatial/executive, naming, memory, attention, language, abstraction, delayed recall and orientation. Montreal Cognitive Assessment score is calculated by adding the points of the tasks successfully completed, and it ranges from 0 to 30 points, being that higher scores indicate better cognitive performance.

Measure: Change in cognitive performance evaluated through Montreal Cognitive Assessment

Time: 6 months after the beginning of the intervention

Description: It's a 32-item mild cognitive impairment screening instrument that assesses eight cognitive functions: visuospatial/executive, naming, memory, attention, language, abstraction, delayed recall and orientation. Montreal Cognitive Assessment score is calculated by adding the points of the tasks successfully completed, and it ranges from 0 to 30 points, being that higher scores indicate better cognitive performance.

Measure: Change in cognitive performance evaluated through Montreal Cognitive Assessment

Time: 12 months after the beginning of the intervention

Secondary Outcomes

Description: Significant statistic improvement in the participant's test scores between pre-intervention, intra-intervention and postintervention assessments. Geriatric Depression Scale -15 is a screening test for depressive symptoms in elderly adults. Assesses depression in the elderly by distinguishing between depressive and dementia symptoms. This instrument does not include somatic conditions common to the elderly, such as appetite, sleep or sexual disturbances, or lower energy level. The overall score ranges from 0 to 15. The higher the score, the greater the severity of the depressive symptoms.

Measure: Depressive symptoms evaluated through Geriatric Depression Scale -15

Time: Pre intervention

Description: Significant statistic improvement in the participant's test scores between pre-intervention, intra-intervention and postintervention assessments. Geriatric Depression Scale -15 is a screening test for depressive symptoms in elderly adults. Assesses depression in the elderly by distinguishing between depressive and dementia symptoms. This instrument does not include somatic conditions common to the elderly, such as appetite, sleep or sexual disturbances, or lower energy level. The overall score ranges from 0 to 15. The higher the score, the greater the severity of the depressive symptoms.

Measure: Change in depressive symptoms evaluated through Geriatric Depression Scale -15

Time: 6 months after the beginning of the intervention

Description: Significant statistic improvement in the participant's test scores between pre-intervention, intra-intervention and postintervention assessments. Geriatric Depression Scale -15 is a screening test for depressive symptoms in elderly adults. Assesses depression in the elderly by distinguishing between depressive and dementia symptoms. This instrument does not include somatic conditions common to the elderly, such as appetite, sleep or sexual disturbances, or lower energy level. The overall score ranges from 0 to 15. The higher the score, the greater the severity of the depressive symptoms.

Measure: Change in depressive symptoms evaluated through Geriatric Depression Scale -15

Time: 12 months after the beginning of the intervention

Description: Significant statistic improvement in the participant's test scores between pre-intervention assessment and postintervention assessment. Quality of Life - Alzheimer's Disease is an instrument to assess quality of life in people diagnosed with dementia, gathering information from the patient and the caregiver. It is composed by 13 items regarding perception of health, mood, functional abilities, interpersonal relationships and hobbies, decision making ability and life in general. It has good psychometric characteristics and it's use has been recommended to evaluate psychosocial interventions. Scores range between 13 - 52 points. Higher scores indicate better quality of life.

Measure: Quality of life evaluated through Quality of Life - Alzheimer's Disease: score

Time: Pre-intervention

Description: Significant statistic improvement in the participant's test scores between pre-intervention assessment and postintervention assessment. Quality of Life - Alzheimer's Disease is an instrument to assess quality of life in people diagnosed with dementia, gathering information from the patient and the caregiver. It is composed by 13 items regarding perception of health, mood, functional abilities, interpersonal relationships and hobbies, decision making ability and life in general. It has good psychometric characteristics and it's use has been recommended to evaluate psychosocial interventions. Scores range between 13 - 52 points. Higher scores indicate better quality of life.

Measure: Change in quality of life evaluated through Quality of Life - Alzheimer's Disease: score

Time: 6 months after the beginning of the intervention

Description: Significant statistic improvement in the participant's test scores between pre-intervention assessment and postintervention assessment. Quality of Life - Alzheimer's Disease is an instrument to assess quality of life in people diagnosed with dementia, gathering information from the patient and the caregiver. It is composed by 13 items regarding perception of health, mood, functional abilities, interpersonal relationships and hobbies, decision making ability and life in general. It has good psychometric characteristics and it's use has been recommended to evaluate psychosocial interventions. Scores range between 13 - 52 points. Higher scores indicate better quality of life.

Measure: Change in quality of life evaluated through Quality of Life - Alzheimer's Disease: score

Time: 12 months after the beginning of the intervention

Description: It's an instrument that assesses the independence level of the elderly people regarding IADL's. A score is assigned according to the person's ability to perform a given task. A set of three, four or five options is suggested for each question, which is scored from 1 to 3, 1 to 4 or 1 to 5 points. The highest score corresponds to a greater degree of dependency. If a task does not apply because the person did not perform it in the pre-morbid period, the score for that task is not included in the total score, that is, the maximum possible score includes only the maximum scores of the tasks that the person performed. The score ranges from 8 to 30 points (a score of 8 points means that th person is independent; between 9 and 20 points means a moderate dependency; greater than 20 points means severe dependency).

Measure: Functional status is assessed using the Lawton and Brody Instrumental Activities of Daily Living.

Time: Pre-intervention

Description: It's an instrument that assesses the independence level of the elderly people regarding IADL's. A score is assigned according to the person's ability to perform a given task. A set of three, four or five options is suggested for each question, which is scored from 1 to 3, 1 to 4 or 1 to 5 points. The highest score corresponds to a greater degree of dependency. If a task does not apply because the person did not perform it in the pre-morbid period, the score for that task is not included in the total score, that is, the maximum possible score includes only the maximum scores of the tasks that the person performed. The score ranges from 8 to 30 points (a score of 8 points means that th person is independent; between 9 and 20 points means a moderate dependency; greater than 20 points means severe dependency).

Measure: Change in functional status is assessed using the Lawton and Brody Instrumental Activities of Daily Living.

Time: 6 months after the beginning of the intervention

Description: It's an instrument that assesses the independence level of the elderly people regarding IADL's. A score is assigned according to the person's ability to perform a given task. A set of three, four or five options is suggested for each question, which is scored from 1 to 3, 1 to 4 or 1 to 5 points. The highest score corresponds to a greater degree of dependency. If a task does not apply because the person did not perform it in the pre-morbid period, the score for that task is not included in the total score, that is, the maximum possible score includes only the maximum scores of the tasks that the person performed. The score ranges from 8 to 30 points (a score of 8 points means that th person is independent; between 9 and 20 points means a moderate dependency; greater than 20 points means severe dependency).

Measure: Change in functional status is assessed using the Lawton and Brody Instrumental Activities of Daily Living.

Time: 12 months after the beginning of the intervention

Other Outcomes

Description: Sociodemographic data will be collected using a sociodemographic questionnaire, designed specifically for this study, regarding information about age, gender, literacy, health conditions, among others.

Measure: Sociodemographic data collected through a sociodemographic questionnaire

Time: Pre-intervention

Description: Adherence to the intervention and dropouts will be assessed using a session form, designed specifically for this study, completed by the technician after each session, regarding the attendance and mood/behavior of the participants throughout the intervention sessions.

Measure: Adherence to the intervention and dropouts evaluated through a session form

Time: [Pre, intra (6 months) and post intervention (12 months)]
7 A Randomized, Unblinded, 60-subject Three-wave Clinical Trial of an Occupational Therapy-led In-home Intervention Designed to Help Older Adults Successfully Transition to Their Homes Following a Skilled Nursing Facility Discharge

This clinical study is designed to test the feasibility of a new intervention, CAPABLE Transitions. CAPABLE Transitions is based on the Community Aging in Place, Advancing Better Living for Elders (CAPABLE) intervention designed by Dr. Sarah Szanton at Johns Hopkins University. Similar to CAPABLE, CAPABLE Transitions consists of an occupational therapy (OT)-led intervention in which the study OT, nurse, and handyman deliver an in-home intervention over 3-4 months. This intervention is designed to help with the transition of care from the skilled nursing facility to home as well as to optimize functioning and home safety. This clinical study plans to recruit a total of 60 older adults with and without dementia admitted to a home health agency following discharge from a skilled nursing facility. Given that this is a feasibility study, it is not designed or powered to test hypotheses.

NCT04460742
Conditions
  1. Care Transitions
  2. Dementia
Interventions
  1. Behavioral: CAPABLE Transitions
  2. Behavioral: Home Health Agency Care
MeSH:Dementia
HPO:Dementia

Primary Outcomes

Description: The study will monitor how many older adults are screened and satisfy the eligibility criteria.

Measure: Proportion of participants screened as eligible

Time: Through study completion, an average of 3 years

Description: The study will monitor how many older adults who satisfy the eligibility criteria are enrolled in the study.

Measure: Proportion of screened participants that enroll

Time: Through study completion, an average of 3 years

Description: The study will monitor the proportion of participants that complete the study.

Measure: Proportion of enrolled participants that are retained

Time: 6 months

Description: Participants and study partners will be asked Likert-item response survey questions to assess the perceived benefit and burdensomeness of the intervention.

Measure: Proportion of participants who perceive a benefit from the intervention

Time: 3 months

Description: Participants and study partners will be asked Likert-item response survey questions to assess the perceived benefit and burdensomeness of the intervention.

Measure: Proportion of participants who perceive a benefit from the intervention

Time: 6 months

Description: The study will review audio recordings and study interventionists' documentation to examine fidelity to the intervention and score whether the interventionists completed the central tasks of CAPABLE Transitions. The study will score completion of the critical components as "yes" or "no" and this outcome will be reported as the proportion of critical components of the CAPABLE Transitions intervention that were completed by the occupational therapist and registered nurse.

Measure: Proportion of Critical Tasks Completed

Time: Throughout Study Intervention, an average of 5 months

Description: The study will monitor the proportion of participants who have complete information on home time, quality of life, and health services utilization at 3 months.

Measure: Data Completeness on Clinical Outcomes

Time: 3 months

Description: The study will monitor the proportion of participants who have complete information on home time, quality of life, and health services utilization at 6 months.

Measure: Data Completeness on Clinical Outcomes

Time: 6 months

Secondary Outcomes

Description: Home time is the number of days participants spend alive in non-institutional settings (e.g., nursing homes and hospitals). The study will report the participants' home time at 3 months of follow-up.

Measure: Home Time in Days

Time: 3 months

Description: Home time is the number of days participants spend alive in non-institutional settings (e.g., nursing homes and hospitals). The study will report the participants' home time at 6 months of follow-up.

Measure: Home Time in Days

Time: 6 months

Description: The study will examine quality of life (EQ-5D-5L) among study participants at 3 months of follow-up. Rating: mobility, self-care, usual activities, pain/discomfort and anxiety/depression, each with 1 as lowest score and 5 as highest score: no problems, slight problems, moderate problems, severe problems and extreme problems, where higher scores indicate worse outcome. The EQ VAS question records the patient's self-rated health on a vertical visual analogue scale, where the endpoints are labelled 'The best health you can imagine' and 'The worst health you can imagine' out of 100. Therefore higher scores may indicate better outcomes.

Measure: Mean change in quality of life using EQ-5D-5L (unabbreviated title)

Time: 3 months

Description: The study will examine quality of life (EQ-5D-5L) among study participants at 6 months of follow-up. Rating: mobility, self-care, usual activities, pain/discomfort and anxiety/depression, each with 1 as lowest score and 5 as highest score: no problems, slight problems, moderate problems, severe problems and extreme problems, where higher scores indicate worse outcome. The EQ VAS question records the patient's self-rated health on a vertical visual analogue scale, where the endpoints are labelled 'The best health you can imagine' and 'The worst health you can imagine' out of 100. Therefore higher scores may indicate better outcomes.

Measure: Mean change in quality of life using EQ-5D-5L (unabbreviated title)

Time: 6 months

Description: The study will examine the proportion of participants who went to the emergency department, were hospitalized, and were admitted to a skilled nursing facility within 3 months of follow-up. The study also will tabulate the mean number of times they used these services within 3 months of follow-up.

Measure: Health Services Use

Time: 3 Months

Description: The study will examine the proportion of participants who went to the emergency department, were hospitalized, and were admitted to a skilled nursing facility within 6 months of follow-up. The study also will tabulate the mean number of times they used these services within 6 months of follow-up.

Measure: Health Services Use

Time: 6 Months

HPO Nodes


HP:0000726: Dementia
Genes 290
C9ORF72 HNRNPA2B1 DNAJC13 HTT CHCHD10 HNRNPA1 CLN6 FMR1 PSAP ATXN10 TOMM40 GBA ATXN3 PSEN1 ADH1C GBA2 CHMP2B COX1 TREM2 POLG NOTCH3 PLAU TRNF AARS2 PINK1 VPS13C TBP SYNJ1 MAPT ATXN8OS UCHL1 PSEN1 SNCA FUS TYMP SLC13A5 TRNC PLA2G6 MATR3 EPM2A SNCA C19ORF12 PANK2 SNCA CP PPP2R2B CHMP2B HTT TRNK TRNL1 ND1 ND4 PDGFB RRM2B NR4A2 ERCC8 MPO VPS13A LRRK2 SERPINI1 JPH3 PODXL GIGYF2 ITM2B WDR45 PRNP COX3 TRNQ DNMT1 SPAST SDHB ABCD1 C9ORF72 PRNP GBA PSEN2 NPC2 LRRK2 SQSTM1 GBA TRPM7 CYTB SNCA TRNV MAPT RNF216 HTRA1 COX3 COL4A1 CYP27A1 GRN FTL FMR1 TUBA4A TWNK APP ALDH18A1 MMACHC VPS13C MAPT MBTPS2 TMEM106B SQSTM1 ATP13A2 SPG21 ATN1 APTX GBA HEXA ATP6V0A2 PARK7 ALDH18A1 WDR45 DGUOK HTRA2 ARSA NOTCH2NLC TRNS2 ROGDI MAPT KCTD7 WFS1 TREM2 CISD2 TRNQ VPS35 APOE GBA PRNP PSEN2 HTT TBP HFE CLN3 NHLRC1 TRNS1 UBQLN2 GRN CHCHD10 PNPLA6 TRNH VCP SDHD HTRA1 TYROBP ZFYVE26 HNRNPA2B1 NPC1 TREM2 C9ORF72 SLC2A3 PSEN1 MAPT TYROBP TARDBP CP TREM2 PANK2 DNMT1 RNF216 PINK1 MATR3 ATP6V1A PLA2G6 SNCA SDHAF1 MAPT GRN CSF1R TTR XPR1 COX2 TRNF SDHA VCP SNCAIP SORL1 LRRK2 GRN ATXN2 TARDBP SCARB2 TRNW ATP7B APP GM2A PRDM8 TBK1 PDGFRB PRICKLE1 ATP13A2 IRF6 APOE ROGDI POLG PSEN1 ATXN2 CHMP2B PSEN1 APP PRKAR1B VCP ATP13A2 PRNP ITM2B ATP6 NHLRC1 ATP13A2 TBK1 TRNS2 ASAH1 NOS3 APP A2M EPM2A CSTB DNAJC5 COX1 CTSF CERS1 CHMP2B SQSTM1 WFS1 TRNW TUBB4A APP ATN1 PRNP ND5 C9ORF72 JPH3 SPG21 RAB39B PRKN ND6 MAPT ATXN2 DCTN1 ND5 ABCA7 APP SNCB CUBN PRNP PRNP FBXO7 ERCC4 HLA-DQB1 PSEN1 NDP C9ORF72 TREX1 DCTN1 PRDX1 PPP2R2B VCP TMEM106B SNCA CFAP43 PSEN1 VCP TRNE GBA2 APP NOTCH3 TRNS1 COX2 ATP6V1E1 TREM2 TIMM8A FTL VCP CHMP2B MAPT MECP2 ATP6 MAPT TMEM106B EIF4G1 DNM1L ND6 ADA2 ASAH1 GBE1 TRNL1 CST3 ND1 GLUD2 OPA1 DNAJC6
Protein Mutations 1
V158M
SNP 0

HPO

Alphabetical listing of all HPO terms. Navigate: Correlations   Clinical Trials


HPO Nodes


HP:0000726: Dementia
Genes 290
C9ORF72 HNRNPA2B1 DNAJC13 HTT CHCHD10 HNRNPA1 CLN6 FMR1 PSAP ATXN10 TOMM40 GBA ATXN3 PSEN1 ADH1C GBA2 CHMP2B COX1 TREM2 POLG NOTCH3 PLAU TRNF AARS2 PINK1 VPS13C TBP SYNJ1 MAPT ATXN8OS UCHL1 PSEN1 SNCA FUS TYMP SLC13A5 TRNC PLA2G6 MATR3 EPM2A SNCA C19ORF12 PANK2 SNCA CP PPP2R2B CHMP2B HTT TRNK TRNL1 ND1 ND4 PDGFB RRM2B NR4A2 ERCC8 MPO VPS13A LRRK2 SERPINI1 JPH3 PODXL GIGYF2 ITM2B WDR45 PRNP COX3 TRNQ DNMT1 SPAST SDHB ABCD1 C9ORF72 PRNP GBA PSEN2 NPC2 LRRK2 SQSTM1 GBA TRPM7 CYTB SNCA TRNV MAPT RNF216 HTRA1 COX3 COL4A1 CYP27A1 GRN FTL FMR1 TUBA4A TWNK APP ALDH18A1 MMACHC VPS13C MAPT MBTPS2 TMEM106B SQSTM1 ATP13A2 SPG21 ATN1 APTX GBA HEXA ATP6V0A2 PARK7 ALDH18A1 WDR45 DGUOK HTRA2 ARSA NOTCH2NLC TRNS2 ROGDI MAPT KCTD7 WFS1 TREM2 CISD2 TRNQ VPS35 APOE GBA PRNP PSEN2 HTT TBP HFE CLN3 NHLRC1 TRNS1 UBQLN2 GRN CHCHD10 PNPLA6 TRNH VCP SDHD HTRA1 TYROBP ZFYVE26 HNRNPA2B1 NPC1 TREM2 C9ORF72 SLC2A3 PSEN1 MAPT TYROBP TARDBP CP TREM2 PANK2 DNMT1 RNF216 PINK1 MATR3 ATP6V1A PLA2G6 SNCA SDHAF1 MAPT GRN CSF1R TTR XPR1 COX2 TRNF SDHA VCP SNCAIP SORL1 LRRK2 GRN ATXN2 TARDBP SCARB2 TRNW ATP7B APP GM2A PRDM8 TBK1 PDGFRB PRICKLE1 ATP13A2 IRF6 APOE ROGDI POLG PSEN1 ATXN2 CHMP2B PSEN1 APP PRKAR1B VCP ATP13A2 PRNP ITM2B ATP6 NHLRC1 ATP13A2 TBK1 TRNS2 ASAH1 NOS3 APP A2M EPM2A CSTB DNAJC5 COX1 CTSF CERS1 CHMP2B SQSTM1 WFS1 TRNW TUBB4A APP ATN1 PRNP ND5 C9ORF72 JPH3 SPG21 RAB39B PRKN ND6 MAPT ATXN2 DCTN1 ND5 ABCA7 APP SNCB CUBN PRNP PRNP FBXO7 ERCC4 HLA-DQB1 PSEN1 NDP C9ORF72 TREX1 DCTN1 PRDX1 PPP2R2B VCP TMEM106B SNCA CFAP43 PSEN1 VCP TRNE GBA2 APP NOTCH3 TRNS1 COX2 ATP6V1E1 TREM2 TIMM8A FTL VCP CHMP2B MAPT MECP2 ATP6 MAPT TMEM106B EIF4G1 DNM1L ND6 ADA2 ASAH1 GBE1 TRNL1 CST3 ND1 GLUD2 OPA1 DNAJC6
Protein Mutations 1
V158M
SNP 0

Reports

Data processed on September 26, 2020.

An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.

Drug Reports   MeSH Reports   HPO Reports  

Interventions

4,180 reports on interventions/drugs

MeSH

691 reports on MeSH terms

HPO

263 reports on HPO terms

All Terms

Alphabetical index of all Terms

Google Colab

Python example via Google Colab Notebook